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Salmonella enterica serovar Typhi
S U M M A R Y
Objectives: We hypothesized that Salmonella enterica serovar Typhi (S. Typhi) with higher bioﬁlm and
capsule production capability are more able to survive continuously in typhoid patients/carriers, with
subsequent prolonged shedding in feces.
Methods: Bacterial cell release from bioﬁlm (produced in vitro and conﬁrmed by speciﬁc staining and
electron microscopy) and comparative cytotoxicity were studied on Caco2 cells. Functionality of the
bioﬁlm diffusion barrier was tested against ciproﬂoxacin. Bioﬁlm production was graded and semi-
quantiﬁed as , +, ++, +++, and ++++.
Results: Out of 30 isolates, 23 produced bioﬁlm. The average post-treatment detection of S. Typhi in
blood was 7–13 days and in stool was 13–32 days. A fall in cell count from 104 to approximately 101 over
the course of 3 days as compared to total elimination of planktonic cells in 16 h after ciproﬂoxacin
application substantiated the protective role of bioﬁlm. Lactic dehydrogenase release ranged from 38% in
non-bioﬁlm producers to 97% in the highest bioﬁlm producers, indicating increased pathogenic
behavior.
Conclusions: The period of S. Typhi clearance from typhoid patients after recovery was found to be
directly related to bioﬁlm production capability.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Bacterial bioﬁlms are the predominant mode of bacterial
growth, reﬂected in the observation that approximately 80% of all
bacterial infections are related to bioﬁlms.1,2 Bioﬁlms are deﬁned
as structured communities of bacterial cells enclosed in a self-
produced polymeric matrix adherent to inert or living surfaces.3–5
Salmonella enterica serovar Typhi (S. Typhi), the causative agent
of typhoid in humans, is also capable of producing bioﬁlms; this
contributes to its resistance and persistence in the host. S. Typhi is
transmitted through the fecal–oral route by contaminated water
and food. Typhoid is communicable for as long as the infected
person is capable of excreting bacteria in stool. These bacteria
usually disappear from the stool about a week after symptoms of
illness have resolved. However, a percentage of these infections
can result in asymptomatic carriage of salmonellae, possibly due to
the formation of bioﬁlms as a mechanism that contributes to the
development of the carrier state.6* Corresponding author. Tel.: +92 41 2651475/79 ext. 240; fax: +92 41 2651472.
E-mail address: ahaq_nibge@yahoo.com (A. Haque).
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against environmental stresses, antibiotics,7 disinfectants, and the
host immune system,8 and as a consequence are extremely
difﬁcult to eradicate.9 Planktonic Salmonella populations are found
to be sensitive to different antibiotics as compared to bioﬁlms. It is
reported that Salmonella enterica serovar Typhimurium bioﬁlms
pre-formed on microplates are up to 2000-fold more resistant to
ciproﬂoxacin as compared to planktonic cells.10 This is particularly
concerning, as ciproﬂoxacin is commonly used to treat Salmonella
infections.11
Traditionally, the ability of S. Typhi to cause disease and to
induce a protective immune response is attributed to possession of
a capsule that is polysaccharide in nature. Yet it is also well known
that S. Typhi can cause disease in the absence of capsule.12,13 As
bioﬁlm has a protective role similar to capsule, we hypothesized
that its presence may have a shielding role and be a basis for longer
survival in the body, thus substantiating the carrier status.
This study was designed to evaluate the possible role of bioﬁlm
produced by S. Typhi on delayed clearance of bacteria (extended
carrier state) from the body in association with the presence of the
outer capsular polysaccharide, and the comparative efﬁcacy of
anti-typhoidal drugs, especially ciproﬂoxacin, against planktonic
and bioﬁlm phase bacteria.ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Clinical samples
Clinically suspected cases of typhoid (both sexes; age range 8–
55 years) with a fever of 3–20 days duration and most of the
following symptoms were studied: enlarged spleen, headache,
rose spots, malaise, abdominal discomfort, lethargy, constipation
followed by diarrhea, fatigue, delirium, and agitation. One
hundred patients who were PCR-positive (targeting the ﬂiC gene)
and were due to receive standard typhoid treatment were
included. Clinical specimens were collected on the same day or
within 1–2 days after the ﬁrst consultation. Series of blood and
stool samples were collected (twice a week) from each patient
until the PCR became negative for at least two consecutive
collections. Blood samples were collected simultaneously in
potassium EDTA (20 mM) BD Vacutainer for PCR and in sterilized
tryptic soy broth (TSB) for blood culture (1:8), while stool samples
were collected in sterile containers containing glycerol saline
buffer (dipotassium phosphate 22.7 mM (3.1 g/l), monopotas-
sium phosphate 7 mM (1 g/l), phenol red (0.003 g/l), sodium
chloride 72 mM (4.2 g/l)). Samples that were blood culture-
positive (28 out of 100) and identiﬁed as S. Typhi by conventional
biochemical and molecular methods,14,15 were selected for
further study. These isolates were subcultured in TSB overnight,
and tested for Vi antigen by corresponding antiserum (Bio-Stat,
UK); aliquots were preserved in 20% glycerol and stored at 20 8C
until further use. When required, an aliquot of the stored S. Typhi
isolate was revived in TSB for 24 h at 37 8C.
2.2. Polymerase chain reaction (PCR)
DNA was extracted from blood as described previously.16
Brieﬂy, 1 ml of blood containing 20 mM potassium EDTA as
anticoagulant was centrifuged at 10 000 rpm (Sorvall Legend RT)
for 5 min. Plasma was separated for serology. The pellet was
resuspended in 1 ml of lysis buffer (0.2% Triton X-100 in Tris–HCl
(pH 8.0)). The mixture was gently aspirated several times to
encourage efﬁcient hemolysis. The tube was centrifuged at
12 000 rpm (Sorvall Legend RT) for 6 min, the supernatant was
discarded, and the procedure was repeated. The pellet was washed
with distilled water. The supernatant was removed, and the pellet
was subsequently resuspended in 20–30 ml of distilled water. The
tubes were sealed and then sterilized in boiling water for 20 min.
Extraction of bacterial DNA from fecal samples was performed
according to Frankel et al.17
Molecular detection of S. Typhi was done targeting the ﬂiC gene
by regular primers ST1 50-TATGCCGCTACATATGATGAG-30 and ST2
50-TTAACGCAGTAAAGAGAG-30, and nested primers ST3 50-ACTGC-
TAAAACCACTACT-30 and ST4 50-TGGAGACTTCGGTCGCGTAG-30;15
conditions have been described previously.18 The viaB operon, and
type IV B pili, which are essential for capsule formation and
bacterial attachment, were detected in all S. Typhi isolates by
targeting the tviA and pilS genes, respectively.19 Two reference
strains NIB25 and NIB38,19 were used as negative and positive
controls, respectively, for both the viaB operon and type IV B pili.
Oligonucleotides and enzymes used in the study were supplied by
Fermentas (Maryland, USA). Amplicons were separated on a 2%
agarose gel at 100 V for 60 min and photographed using Gel
DocTM-XR imaging system (Bio-Rad Laboratories, Inc., Hercules,
CA, USA).
2.3. Bioﬁlm production by S. Typhi
After detection and conﬁrmation of S. Typhi isolates and
evaluation of their Vi status with PCR, we followed the reportedmethodology for the production of bioﬁlms.20 However, as
adherence test medium (ATM) failed to produce bioﬁlm, we used
modiﬁed bioﬁlm production medium, which was optimized to
contain 60 mM NaCl, 20 mM KCl, 110 mM glucose, 30 mM
Na2HCO3, 20 mM NH4Cl, 40 mM K2HPO4, 50 mM (NH4)H2PO4,
1 mM CaCl2, 980 mM MgCl2, 86 mM FeCl3, and 40 mM Na2SO4. The
suspension was placed in grease-free sterilized sealed test tubes in
triplicate and incubated with mild shaking (170 rpm) at 37 8C for
24 h. For semi-quantitative grading we developed a reference that
subdivided the S. Typhi isolates into ﬁve categories, ranging from
no bioﬁlm production () to maximum bioﬁlm production (++++).
2.4. Crystal violet staining of bioﬁlm
Crystal violet staining of bioﬁlm was done following the
methodology described elsewhere.21 Brieﬂy, planktonic phase
cells were aspirated and bioﬁlm ring was washed with a
continuous spray of 1 phosphate buffered saline (PBS; pH 6.8)
and incubated at room temperature for 1 h to ﬁx the cells. Crystal
violet (1% in isopropanol–methanol–1 PBS; 1:1:18) was poured
into each test tube. Test tubes were incubated for 15 min at room
temperature and washed thoroughly with 1 PBS (pH 6.8) until
the buffer ran clear. Bioﬁlm was then immersed in 33% acetic acid
to extract the dye. Dye retained by the bacterial cells was measured
at 570 nm. For quantiﬁcation, a standard graph of crystal violet in
33% acetic acid was made. Dye retained by the bacterial cells was
measured at 570 nm in batches of six.
2.5. Transmission electron microscopy (TEM) of bioﬁlm
Samples from the interface, planktonic phase, and TSB were
analyzed using TEM (Jeol 1010, Japan). For micro-encapsulation
method, agar (3%) blocks with bioﬁlm samples were prepared,
thinly sliced, and studied under TEM. Direct analysis of bioﬁlm
matrix on AEI carbon-coated grids was done. Bacterial bioﬁlm
suspension was placed onto the grid and the bacteria were allowed
to adhere for 2 min and then ﬁxed for 1 min with 1.5%
glutaraldehyde in sodium cacodylate buffer (100 mM, pH 7.4).
The grids were rinsed twice with water and negatively stained
with 0.75% (wt/vol) uranyl acetate (pH 6.4) for 1 min. The grids
were drained and subjected to microscopic studies.
2.6. Antibiotic susceptibility assay
Four commonly used antibiotics for typhoid were employed to
compare susceptibility patterns of bioﬁlm resident and plankton-
ic phase bacteria. Pieces of bioﬁlm were cultured in 5 ml TSB
overnight, whereas for planktonic bacteria, 50 ml of inoculated
medium from the same tube was added to 5 ml of TSB and
incubated overnight. The antimicrobial susceptibility patterns
were determined as per the Clinical and Laboratory Standards
Institute (CLSI) recommendations,22 using the following com-
mercial antimicrobial disks (HiMedia, India): chloramphenicol
(30 mg), ampicillin (10 mg), ciproﬂoxacin (5 mg), and trimetho-
prim (30 mg).
2.7. Ciproﬂoxacin penetration assay
Bioﬁlm was exposed to 1 mg/ml of ciproﬂoxacin. Planktonic
phase cells were also transferred, essentially without dilution, into
fresh antibiotic-containing growth medium. Colony count experi-
ments were performed in parallel. For the penetration assay,
bioﬁlm produced was exposed to ciproﬂoxacin for speciﬁed time
intervals of 4, 8, 12, 16, 20, 24, 36, 48, 60, and 72 h. After exposure
to ciproﬂoxacin, the bioﬁlm gummy material was used for colony
count experiments.
Table 1
LDH release assay for cytotoxicity after exposure to ciproﬂoxacin (1 mg/ml)
Cytotoxicity of escapers Ciproﬂoxacin penetration
LDH release (A490/655) % Cytotoxicity % Bactericidal activity
Control (media) 0.16  0.04
Control (Triton X) 1.55  0.31
Control positive (free S. Typhi culture) 1.48  0.40 Taken as 100% 100% after 16 h
After (h):
4 1.11  0.03 74.65 30
8 0.98  0.23 60.95 40
12 0.81  0.05 55.47 52
16 0.83  0.02 56.84 60
20 0.75  0.3 52.73 65
24 0.78  0.04 47.94 63
36 0.71  0.31 47.26 79
48 0.60  0.41 39.04 85
60 0.48  0.05 30.13 88
72 0.41  0.08 27.39 94
LDH, lactate dehydrogenase.
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We used the increase in LDH release to show if S. Typhi cells in
bioﬁlm are more pathogenic than planktonic cells. Human colon
epithelial cell line Caco2 was used for the assessment of LDH
release.23 Caco2 cells ATCC (Rockville, MD, USA) were grown in
Dulbecco’s modiﬁed Eagles medium (DMEM) as monolayers and
trypsinized. Viability counts were done by trypan blue (0.4%)
staining to assess the suitability for further experimentation.23
Bioﬁlm was produced in a 96-well plate, and 200 ml of Caco2 cell
suspension was added for selected time periods (4, 8, 12, 16, 20, 24,
36, 48, 60, and 72 h, Table 1). The cell suspension was aspirated
after a speciﬁed time and centrifuged (3000  g, 5 min) to remove
debris. A 0.1-ml aliquot was dispensed into a 96-well microtiter
plate, and 0.1 ml/well of LDH substrate was added. Plates were
read after 10 min of incubation at room temperature using a plate
reader (Bio-Rad, Hercules, USA) at 490/655 nm. For the purpose of
calculating cytotoxicity values, background LDH release from
tissue culture cells was considered as low (media) control and
Triton-X 100 (0.01%) treated cells as high control. The experiment
was performed with high-grade bioﬁlm producing S. Typhi isolates
in batches of eight.
2.9. Statistical analysis
Analysis of variance was used to determine the differences among
all four bioﬁlm groups (high, medium, low, and non-bioﬁlmFigure 1. In vitro glass adherence test for Salmonella Typhi bioﬁlm production.
Bioﬁlm production reference for S. Typhi isolates: 24 h growth in modiﬁed bioﬁlm
production medium at 170 rpm at 37 8C. Bioﬁlm production was graded (from left
to right) as ++++, +++, ++, +, and , respectively.producers). The Tukey test was applied to check the differences
between each two of the bioﬁlm groups, and the mean difference
was considered as signiﬁcant at the 0.05 level. Data were analyzed
using statistical software SPSS version 16 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Bioﬁlm production
Forty percent (12/30) of the isolates were able to produce a high
level of bioﬁlm (grade ++++ and +++), 16.7% (5/30) medium (++),
20% (6/30) low grade (+), and 23.3% (7/30) were unable to produce
bioﬁlm (Figure 1). These results included the reference strains.
3.2. Bioﬁlm matrix analysis
Electron microscopy conﬁrmed the presence of bioﬁlm matrix
(Figure 2). Cells were found to be embedded in the form of macro-
colonies at the interface (Figure 2A) as compared to planktonic
phase cells in the middle of the test tube (Figure 2B). The bioﬁlm,
which appeared as a slimy whitish gunk to the naked eye, was
observed as multicellular communities attached by water channels
that are represented by thread-like structures in TEM images.
Without shaking no bioﬁlm was produced; only aggregation in the
middle of the test tube was observed. An increase in polysaccha-
ride formation was observed after 24 h. Crystal violet staining
conﬁrmed the bioﬁlm production.
3.3. Bioﬁlm production phenomenon in relation to clearance of S.
Typhi from the body
Post-treatment, the last day of S. Typhi detection in blood
ranged from 10–15 days (mean 13.125  1.96) in high bioﬁlm
producers to 7–15 days (mean 9.8  3.27) in medium producers, 8–
11 days (mean 8.88  1.21) in low-grade producers, and 5–10 days
(mean 6.85  1.67) in non-bioﬁlm producers. Similarly, the last day of
detection of S. Typhi in feces had a mean value of 32.25  12.78 days
in high-grade bioﬁlm producers, 23.6  7.5 days in moderate bioﬁlm
producers, 16.51  2.13 days in low bioﬁlm producers, and
13.28  2.81 days for non-bioﬁlm producers, indicating a role of
bioﬁlm production in the carrier state.
Regarding days to detect the S. Typhi in blood, the comparison of
high bioﬁlm producers with low and non-bioﬁlm producers showed
a signiﬁcant difference (p = 0.04 and p < 0.001 respectively), while
the difference among all other bioﬁlm groups was found to be
non-signiﬁcant (p > 0.05). In the case of detection from stool, only
Figure 2. Transmission electron micrographs of bioﬁlm (Magniﬁcation  23 500).
(A) Bioﬁlm producing Salmonella Typhi. (B) Non-bioﬁlm producers.
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to be signiﬁcant (p = 0.008), and the difference among all other
bioﬁlm groups was found to be non-signiﬁcant (p > 0.05). Details
are given in (Table 2).
3.4. Antibiotic susceptibility of bioﬁlm and planktonic phase cells
Out of 30 isolates, 23 (76%) produced bioﬁlm; 19 were found
resistant to one or more anti-typhoid drugs, i.e., chlorampheni-
col (Cm), ampicillin (A), trimethoprim (T), and ciproﬂoxacin (C).
Of the seven isolates that failed to produce bioﬁlm, four were
found sensitive to all four antibiotics (Table 2). No difference
was found in the resistance patterns of the cells from bioﬁlm
matrix and planktonic phase when tested against all four
antibiotics.
3.5. LDH assay for cytotoxicity
A marked difference in LDH release was observed between the
two categories. More LDH release, 62% to 97%, was observed in
isolates with a high-grade bioﬁlm production level as compared to
non-bioﬁlm producers (i.e., 38% to 57%), showing that bioﬁlm
producers are more cytotoxic (Table 1). The LDH release assay was
also used to study the continuous escape of bacteria from bioﬁlm
for different time intervals of 4 to 72 h. In the ﬁrst 4 h, maximum
cytotoxicity (75%) was observed with more LDH release, which
decreased with time but did not reach 0% in 72 h, showing the
presence of cells (persisters) inside the bioﬁlm (Table 1).
The LDH release from high bioﬁlm producers was found to be
signiﬁcantly higher than in low and non-bioﬁlm producers
(p < 0.001). The difference between medium and non-bioﬁlm
producers was also found to be signiﬁcant (p = 0.008), while the
difference among all other bioﬁlm groups was found to be non-
signiﬁcant (p > 0.05).3.6. Ciproﬂoxacin penetration assay
Evidence for persisters was further strengthened with the
ciproﬂoxacin penetration assay in which the drug was able to
penetrate into the bioﬁlm reducing the cell count from 104 to
approximately 101 over the course of 3 days, although the free
bacteria were totally killed after 16 h of exposure at 1 mg/ml.
Penetration into bioﬁlm was slow (killing almost 30% of cells in the
ﬁrst 4 h and up to 94% after 72 h) (Table 1).
3.7. Virulence status of bioﬁlm producers and non-producers
Of the 30 isolates, seven failed to give any ampliﬁcation for the
tviA gene. All the high-grade bioﬁlm producers produced the
desired amplicon; among medium and low bioﬁlm producers 4/5
and 4/6 were tviA-positive, respectively. The pilS was detected in
all bioﬁlm-producing isolates. The non-bioﬁlm producers showed
variable results; out of seven isolates, three were found positive for
both tviA and pilS, whereas four failed to give any ampliﬁcation for
both genes. Details are described in Table 2.
4. Discussion
Typhoid is communicable for as long as the infected person
excretes S. Typhi in the feces. Despite major treatment and
prevention efforts, millions of new typhoid infections occur
worldwide each year. For a subset of infected individuals, S. Typhi
colonizes systemically, mostly in the gall bladder, and remains
long after symptoms subside, serving as a reservoir for the further
spread of the disease.24 The excretion in stool usually begins about
a week after the onset of illness and continues through
convalescence and for a variable period thereafter.25
Bioﬁlm formation is likely to play a signiﬁcant role in
establishing long-term colonization, and bacterial cells are
continuously shed for extended periods.6 In this study, we tried
to ﬁnd a correlation between this carrier state and the bioﬁlm
production capability of isolates, if any. We found that shedding of
S. Typhi in stool continued for a longer time in patients infected
with high-grade bioﬁlm producers. The maximum period for
shedding of bacteria observed in this study was 50 days (average
32.25 days) post-infection in the case of high bioﬁlm producers,
and this was usually not more than 17 days (average 13.28 days) in
the case of non-bioﬁlm producers. The presence of bioﬁlm in S.
Typhi may thus be related to the length of the carrier state in a
patient after recovery.
Although bioﬁlm production prolonged the carrier state, it
remains to be evaluated whether this was due to the physical
protective effect or to the bioﬁlm bacteria being more resistant as
compared to planktonic phase bacteria. Recently, 194 S. enterica
strains isolated from infected children were investigated for their
ability to form bioﬁlms on silicone disks; these were compared
with corresponding planktonic forms for susceptibility to nine
antimicrobial agents. About 56% of the strains were able to form
bioﬁlms.26 The bioﬁlms showed increased antimicrobial resistance
to all antibiotics as compared to the planktonic bacteria, with the
highest resistance rates for gentamicin (90%) and ampicillin (84%).
Our ﬁndings also show that when the bacterial cells are detached
from bioﬁlm, they show similar drug resistance patterns to the
planktonic phase cells. However, they were more cytotoxic as
shown by increased LDH release from target Caco2 cells.
Real-time penetration of ciproﬂoxacin dropped the cell number
from 104 to approximately 101 at 1 mg/ml, but it was not able to
eliminate 100% of the cells and left the persisters intact. This
ﬁnding is consistent with other reports regarding persisters.10
Once the antibiotic level drops, the persisters may multiply,
explaining the relapsing nature of bioﬁlm infections.
Table 2
Individual characteristics of Salmonella Typhi isolates











tviA gene pilS gene LDH release
1 ST1275 15 30 Cm, T +++ Present Present 1.59
2 ST1389 13 15 A, T ++++ Present Present 1.48
3 ST1594 12 40 A, Cm, T ++++ Present Present 1.57
4 ST1403 14 33 A ++++ Present Present 1.82
5 ST1404 10 15 T ++++ Present Present 1.62
6 ST1413 11 50 A, Cm ++++ Present Present 1.49
7 ST1425 12 20 A, Cm, T, C ++++ Present Present 0.98
8 ST1430 10 14 A, Cm, T, C +++ Present Present 1.51
9 NIB38 15 30 A, Cm, T, C ++++ Present Present 1.58
10 ST1004 10 15 A, Cm, T, C +++ Present Present 1.42
11 1577 15 30 T ++++ Present Present 1.49
12 1670 15 45 Cm ++++ Present Present 1.08
Mean  SD 13.125  1.96 32.25  12.78 1.47  0.23
Min–max 10–15 15–50 0.98–1.82
13 1671-S 10 32 Cm ++ Present Present 1.38
14 1890-XP 7 20 - ++ Present Present 1.42
15 1350-XZ 15 15 T ++ Present Present 1.39
16 1420 10 20 A ++ Absent Present 0.99
17 H56 7 31 A, Cm, T, C ++ Present Present 1.10
Mean  SD 9.8  3.27 23.6  7.5 1.25  0.197
Min–max 7–15 15–32 0.99 –1.42
18 1421 10 17 - + Present Present 1.32
19 1422 9 18 T + Present Present 0.96
20 1429 11 15 - + Present Present 0.90
21 1876 8 20 Cm + Present Present 1.03
22 1987 9 17 A + Absent Present 1.00
23 2534 11 14 - + Absent Present 0.99
Mean  SD 8.88  1.21 16.51  2.13 1.03  0.14
Min–max 8–11 14–20 0.90 –1.32
24 NIB25 6 12 -  Absent Absent
25 1680-S 5 10 -  Present Present
26 1681-S 10 16 -  Absent Absent
27 1423 6 17 -  Present Present
28 1424 8 13 Cm  Present Present
29 1428 7 15 A  Absent Absent
30 1431 6 10 T  Absent Absent
Mean  SD 6.85  1.67 13.28  2.81 0.87  0.076
Min–max 5–10 10–17 0.76–0.99
PCR, polymerase chain reaction; LDH, lactate dehydrogenase; SD, standard deviation.
a Days were counted from the day the disease was diagnosed.
b Cells grown in LB broth/cells from matrix/planktonic phase showed the same pattern: chloramphenicol (Cm), ampicillin (A), trimethoprim (T), ciproﬂoxacin (C).
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infectivity of S. Typhi and the severity of disease in volunteers.27,28
Like bioﬁlm, the Vi capsule, being exopolysaccharide in nature,
may have a signiﬁcant role in bioﬁlm formation and persistence of
infection. But as our data suggest, the viaB operon is found in both
bioﬁlm and non-bioﬁlm producers and thus is not a signiﬁcant
contributor to bioﬁlm production.
The type IV B pilus of the enteropathogenic bacteria S. Typhi is a
major adhesion factor during entry of this pathogen into
gastrointestinal epithelial cells.29 In this study, detection of type
IV B pili in all bioﬁlm producers strongly suggests its preliminary
role in bioﬁlm production. Unfortunately animal models are not
successful for S. Typhi, which is a strict human pathogen, and in
vivo studies are difﬁcult and often inconclusive. Therefore,
considering the difﬁculties regarding in vivo studies to show the
prolonged carrier state, our ﬁndings provide valuable information
in this regard.
In conclusion, it was found that the time to clearance of S. Typhi
from typhoid patients after recovery (as gauged by PCR on stool
samples) is directly related to bioﬁlm production capability. The
period between blood and stool PCR negativity differs from patient
to patient and may extend up to 2 months. The presence of bioﬁlm
does not alter the drug resistance proﬁle of the bacteria, butprovides physical protection which results in delayed clearance
probably due to ‘persisters’. It was also found that the presence of
Vi capsule has no relevance to bioﬁlm production, but that type IV
B pili have a signiﬁcant effect.
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